Drug intelligence / Profile preview

mesoridazine

Development stage
Discontinued
Lead developer
Boehringer Ingelheim
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

Mesoridazine is a phenothiazine antipsychotic, structurally related to thioridazine and classified as a typical antipsychotic. It was primarily used for the management of schizophrenia, especially in patients who did not respond adequately to other antipsychotics. Its mechanism of action involves antagonism at central dopamine receptors (mainly D2), leading to reduced dopaminergic neurotransmission in the brain, which helps alleviate psychotic symptoms such as hallucinations and delusions. Mesoridazine also exhibits central antiadrenergic, antidopaminergic, antiserotonergic, and weak muscarinic anticholinergic effects. The drug was withdrawn from the US market due to its association with life-threatening cardiac arrhythmias (QT prolongation) and sudden death[1][3][5]. It is an active metabolite of thioridazine.

Brand names
SerentilLidanarCalodalLidanil
Other names
MesoridazinaMesoridazinumThioridazine 2-sulfoxideThioridazine2-sulfoxideThioridazine-2-sulfoxideThioridazine thiomethyl sulfoxide
02

Targets

ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)M1 (Muscarinic acetylcholine receptor M1)HTR2A (Serotonin receptor 5-HT2A)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on mesoridazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mesoridazine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call